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Introduction “activation” loop (e.g., p701Thr252 [12]), and the other
(e.g. p701Thr412) is located in the conserved segmentThe p70 S6 kinase (p70S6K) is activated downstream of
insulin and growth factor receptors through a complex carboxyterminal to the catalytic domain, in the sequence
FXXFTY [13, 14]. Modification at either site alone givessequence of multiple phosphorylations. Most steps in this
activation mechanism have been elucidated in consi- significant activation; however, physiologic activation re-
quires the simultaneous phosphorylation at both sites,derable, if not quite complete, detail, primarily through
studies on the p70 isoform [1, 2]. The more recently which creates a strong, positively cooperative site-site in-
identified p70 isoform shares with p70 all of the phos- teraction [15]. In addition, the phosphorylation of either
phorylation sites demonstrated thus far to be of regulatory of these two sites appears to promote the phosphorylation
significance; it is therefore likely that the mechanism of of the other [10, 11]. Considerable evidence indicates
p70 activation will parallel that of p70 [3–5]. These that PDK1 is responsible for the insulin/mitogen-stimu-
kinases contain a centrally located kinase catalytic domain lated phosphorylation of the p70 activation loop (e.g.,
of the AGC subclass, immediately carboxyterminal to p70Thr252). PDK1 phosphorylation catalyzes the direct
which is a segment of approximately 65 amino acids that preferential phosphorylation of this site in vitro. Cotrans-
is highly conserved (approximately 40% identity) among fection of p70 with PDK1 results in p70 activation, con-
most AGC kinases, including the PKBs, PKCs, Rsk comitant with increased phosphorylation at Thr252. Re-
(N-terminal catalytic domain), and SGKs. The p70 se- ciprocally, kinase-inactive ATP site mutants of PDK1
quences flanking these two domains, i.e., an N-terminal block serum/insulin-stimulated phosphorylation of the
segment of 64–88 amino acids and a 104 amino acid car- p70 activation loop [15, 16]. Embryonic stem (ES) cells
boxyterminal tail, are entirely unique to the p70 kinases; lacking PDK1 show no IGF-1-stimulated phosphorylation
each flank contains important regulatory motifs. The ini- of the p70 activation loop [17].
tial step in p70 activation is the phosphorylation of a
cluster of 4–5 (Ser/Thr)Promotifs situatedwithin a psuedo- By contrast, the kinase responsible for the insulin/mito-
gen-stimulated phosphorylation of the p70 hydrophobicsubstrate autoinhibitory domain in the carboxyterminal
noncatalytic tail [6–8]; phosphorylation does not activate site (e.g., p70Thr412) is not known. This site can be
phosphorylated in vitro by the mTOR kinase [18, 19], andp70 catalytic function [9] but serves to dislodge the tail
from the catalytic domain and thereby provides access to its phosphorylation is concomitant with p70 activation.
Subsequent phosphorylation of p70 by PDK1 gives athe activating kinases [10, 11]. Two sites of activating
phosphorylation have been establishedwith certainty; one strongly synergistic increase in p70 activity [19]. Never-
theless, a Rapamycin-resistant p70 mutant (2-46/is located in the p70 catalytic subdomain VIII on the
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CT104) exhibits unimpaired insulin-stimulated phos- antibody, previously employed for the characterization of
p70 Thr412PO4 during transient expression in vivophorylation at the Thr412 site in vivo in the presence of
[10]. The baculoviral recombinant p70CT104 polypep-Rapamycin at concentrations sufficient to fully inhibit
tide substrate showed no ability to catalyze Thr412 phos-the activity of the endogenous mTOR kinase [20]. The
phorylation during incubation in vitro with MgATPp70Thr412 site also undergoes phosphorylation in vivo on
(Figures 1 and 3b).coexpression of p70 with PDK1 [21], and ES cells lacking
PDK1 exhibit no IGF-1-stimulated phosphorylation at
Extracts from HEK293 cells, added directly or afterp70Thr412, although phosphorylation of the homologous
adsorption/elution on Fast Q-Sepharose, gave no detect-site in PKB (Ser473) is unimpaired [17]. PDK1 can phos-
able Thr412 phosphorylation; however, the Fast Q flow-phorylate p70Thr412 directly in vitro, although at a rate
through fraction catalyzed significant Thr412 phosphory-5% the rate at which it phosphorylates p70Thr252. A
lation. This activity was further purified by sequentialfragment of the PKC-related kinase, PRK2, that encom-
adsorption/elution from S-Sepharose, Blue Agarose, andpasses the binding site for PDK1 inhibits PDK1-stimu-
Heparin-Sepharose. The Thr412 kinase activity elutedlated p70Thr412 phosphorylation in vitro, as well as insu-
at each of these steps in a single major peak; however,lin/mitogen-stimulated phosphorylation of p70Thr412 in
purification of HEK293 extracts beyond the Heparin-vivo [21]. These data indicate that PDK1 is critical to
Sepharose step was limited by low recovery. Conse-p70Thr412 phosphorylation in vivo; however, whether
quently, postmicrosomal extracts of rat liver were evalu-this is because of the facilitating effect of Thr252 phos-
ated as an enzyme source and were observed to containphorylation on Thr412 phosphorylation, the direct phos-
a major Thr412 kinase activity that exhibited identicalphorylation of Thr412 by PDK1, the activation of a
chromatographic behavior to that seen with HEK293 ex-Thr412 kinase by PDK1, or some other mechanism re-
tracts. Gel filtration of the Heparin-Sepharose eluatemains to be established.
yielded a single major peak of Thr412 kinase activity at
approximately 35 kDa. Subsequent fractionation of thisWe have partially purified the dominant p70Thr412 ki-
peak on Mono Q anion exchange chromatography gener-nase present in extracts of HEK293 cells; an enzyme with
ally yielded two peaks. In each isolate, the peak thatessentially identical chromatographic behavior was more
eluted at 15–35 mM NaCl contained three polypeptideextensively purified from rat liver and was identified as
bands (Figure 1); each was subjected to tryptic digestiona novel member of the NIMA family of kinases. Further-
and microcapillary RP-HPLC, and peptide sequence in-more, analysis of ESTs revealed a second, closely related
formation was determined by electrospray ionization massgene product. During the course of this work, Kandli et
spectrometry. The spectra obtained from the tryptic di-al [22] identified these sequences as murine ESTs and
gestion of the 35 kDa polypeptide contained four peptidesnamed them NEK6 and NEK7; we have adopted this
that matched with the amino acid sequence of a humannomenclature. The molecular structure and expression of
cDNA, AB026289; a subsequent report described the mu-NEK6 and NEK7, as well as a preliminary functional
rine version of AB026289 asNEK6 [22]. Ourmass spectro-analysis of NEK6, are described in this report. The data
scopic analysis identified an additional five peptides that
indicate that NEK6 and NEK7, which are widely ex- matched with amino acid sequences in murine expressed-
pressed, most highly in liver, are capable of phosphorylat- sequence tag (est) AA102912, subsequently named NEK7.
ing and activating the p70S6K in vitro and in vivo in a A full description of our database search and cDNA clon-
manner that synergizes strongly with PDK1. The NEKs ing of NEK6/7 cDNAs is provided in the Materials and
are thus candidate p70S6K-activating kinases. methods and with this article online in the Supplementary
material. Thus, the 35 kDa p70S6KThr412 kinase we
Results purified from rat liver is probably a mixture of NEK6 and
The p70S6K is phosphorylated at many sites in vivo, and NEK7. Alternatively, this isolate may be entirely NEK7
it can be phosphorylated in vitro at these and other sites in light of the fact that 3 of the 4 peptides attributed to
by numerous protein kinases. We sought to detect the NEK6 are identical in mass and/or sequence in NEK7,
subset of kinases capable of phosphorylating p70Thr412 whereas 3 of the 5 peptides attributed to NEK7 are en-
so as to ascertain their identity and determine whether tirely unique to NEK7. The gene encoding humanNEK6
they participate in the physiologic regulation of p70S6K is situated on chromosome 9, and that encoding NEK7
activity. To this end, we employed as a substrate a bacu- is on human chromosome 1; these two facts indicate that
loviral recombinant p70CT104 mutant, dephosphory- NEK6 and NEK7 are the products of separate genes. A
lated at Thr412 in situ by the treatment of sf9 cells with C. elegans protein kinase (Z50873) is about 75% identical
Rapamycin (0.1 M, 30 min) prior to extraction. The to both NEK6 and NEK7 (Figure 2).
inactive p70CT104 polypeptide was purified to 90%
purity by sequential anion and cation exchange chroma- NEK mRNA expression
tography. The phosphorylation of p70Thr412 was de- cDNA probes reactive selectively with NEK6 or NEK7
were employed for probing a commercial blot containingtected by immunoblot with an anti-Thr412PO4 peptide
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Figure 1
Mono Q fractionation of a p70S6KThr412
kinase activity from rat liver. The dominant
Thr412 kinase activity in a rat liver extract was
purified by sequential chromatography on
Fast Q-Sepharose, SP-Sepharose, Reactive
Blue 4 Agarose, Heparin-Sepharose HiTrap
and Sephacryl S-200 HR gel filtration. (a) The
activity peak from Sephacryl was applied to
a Mono Q column, and Mono Q fractions were
analyzed for p70Thr412 phosphorylation
(anti Thr412PO4 immunoblot, lower panel)
and protein content by Coomassie blue
staining after SDS-PAGE (upper panel).
Similar results were obtained in two other
purifications carried through all steps. The
fractions (14 and 15) containing the peak of
Thr412 kinase activity were pooled and
subjected to SDS-PAGE. (b) The
polyacrylamide gel was stained with
Coomassie blue, and candidate protein
bands (a, b, and c/d) were excised, subjected
to tryptic digestion, microcapillary RP-HPLC,
and peptide sequence determination by
electrospray ionization mass spectrometry.
mRNA extracted from mouse tissues (Figure 2). NEK6 K75 to MM) abolished NEK6-catalyzed p70S6K phos-
phorylation (Figure 3c). As shown by anti-Thr412PO4and NEK7 are most highly expressed in liver. Significant
signals for NEK6 are evident in brain and kidney; low- immunoblotting, NEK6-catalyzed phosphorylation of
p70S6KCT104 (wild-type and K123M) occurs in partlevel expression is evident in all tissues on prolonged
exposure (not shown). NEK7 mRNA is abundant in heart on Thr412, and this component is abolished by muta-
tion of p70Thr412 to Ala (Figure 3b,c). Nevertheless,and kidney and is evident at lower levels in all other
tissues examined. this mutation diminishes overall NEK6-catalyzed
p70S6KCT104 phosphorylation by only 20%-30% (Fig-
ure 3c). Thus, NEK6 corresponds to the p70S6KThr412Recombinant NEK6 phosphorylates p70S6KCT104
kinase purified from liver; however, NEK6 also catalyzesat Thr412
substantial phosphorylation of p70S6K at sites other thanTheNEK6 andNEK7 cDNAswere transiently expressed
Thr412 that are yet to be identified.in HEK293 cells, either as a fusion downstream of GST
or with an N-terminal FLAG epitope, and examined for
their ability to phosphorylate the p70S6K. In vitro, GST- Activation of p70S6KCT104 by NEK6 in vitro
and in intact cells: interaction with PDK1p70S6KCT104 purified from Rapamycin-treated
HEK293 cells exhibits a slight autophosphorylation, which We next examined the effect of NEK6 on p70S6K activity
in the presence and absence of PDK1. Phosphorylationis abolished by mutation of the p70S6K ATP binding site
(K123M). NEK6 catalyzes a time- and concentration- of mammalian recombinant GST-p70SK6CT104 by
NEK6 resulted in a time-dependent increase in p70S6Kdependent phosphorylation of GST-p70S6KCT104
(wild-type and K123M), whereas GST is not phosphory- activity; this increase reached approximately 3-fold at an
overall incorporation of 0.4 mol PO4/mol p70S6K (Figurelated by NEK6 (Figure 3a,c). A comparable amount of
recombinant NEK7 polypeptide, by contrast, phosphory- 4a,b; lane 3 versus lane 1). In parallel, PDK1 catalyzed
the incorporation of approximately 0.15 mol PO4/mollates GST-p70S6KCT104 at 25% of the rate of catalysis
by NEK6 (Supplementary material); further experiments p70S6K (Figure 4a; lane 5 versus lane 1) accompanied by
a very slight (approximately 1.5-fold) increase in p70S6Ktherefore focused on the characterization of recombinant
NEK6. Mutation of the NEK6 ATP binding site (K74 activity (Figure 4b; lane 5 versus lane 1). However, if the
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Figure 2
Amino acid sequence and expression of NIMA
family kinases (NEK) 6 and 7. (a) Alignment
of predicted amino acid sequence of murine
and human NEK6 and murine NEK7 (derived
from overlapping est sequences and PCR from
cDNA libraries; see Materials and methods)
with C. elegans F19H6a.1 and A. nidulans
NIMA. Amino acid number starting from the
initiator methionine is indicated. Conserved
residues are shaded in black, and similar
amino acids are in gray. The 11 subdomains
of a protein kinase are indicated (I-XI). (b)
Expression of NEK6 and NEK7 mRNA in
mouse tissues.
p70S6KCT104 polypeptide is first phosphorylated by for 30 min then gives an activation that is nearly 2-fold
greater than what would be observed if incubation wereNEK6 to a stoichiometry of approximately 0.3 mol PO4/
mol p70S6K (Figure 4a; lane 4), the addition of PDK1 continued with NEK6 alone (Figure 4b; compare lane 4
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Figure 3
to lane 3). The increase in p70S6K activity engendered
by the addition of PDK1 after priorNEK6-catalyzed phos-
phorylation is substantially greater than the sum of the
effects of PDK1 alone (Figure 4b; lane 2  lane 1) plus
NEK6 alone (Figure 4b; lane 3 lane 1). This synergistic
effect is attributable to at least two phenomena; first,
the extent of the PDK1-catalyzed phosphorylation of
p70S6KCT104 is increased nearly 3-fold by the prior
NEK6-catalyzed p70 phosphorylation (Figure 4a; lane 2
lane 1 	 0.05 mol PO4/mol p70S6K, PDK1 alone; lane
4  lane 3 	 0.17 mol PO4/mol p70S6K, PDK1 after
NEK6).This enhancement in the overall PDK1-catalyzed
phosphorylation of p70S6K, however, is not sufficient per
se to account for the concomitant increase in p70 activity.
Simply prolonging the incubation of PDK1 with p70S6K
also enables the incorporation of 0.15 mol PO4/mol
p70S6K (e.g., Figure 4a, lane 5); the resultant increase in
p70 activity (Figure 4b; lane 5  lane 1) is far less than
that achieved by a comparable extent of PDK1-catalyzed
p70S6 phosphorylation occurring concomitantly with
NEK6 (Figure 4b; lane 4  lane 3). The phosphorylation
of Thr412 when NEK6 and PDK1 act concomitantly may
be relatively greater than the sum of the phosphorylation
that occurs when either acts alone (compare Thr412PO4
in Figure 4a, lane 4 to that in lane 3 plus lane 2); however,
we have only qualitative data on this point. It is also likely
that the previously demonstrated, positively cooperative
effect of the concurrent phosphorylation of Thr252 and
Thr412 on p70S6K activity [15] makes an important con-
tribution to the synergistic effect of NEK6 and PDK1 on
p70S6K activity. Notably, the synergism between NEK6
and PDK1 on p70S6K activity is evident primarily when
NEK6 phosphorylation of p70 precedes PDK1 phosphor-
ylation of p70 (Figure 4b; compare lane 4 to lane 2) rather
than the reverse order (Figure 4b; lane 6 versus lane 8),
although the low extent of PDK1-catalyzed phosphoryla-
tion in the latter conditions tempers this conclusion. Thus,
when purified polypeptides were used in vitro, phosphor-
Recombinant NEK6 phosphorylates p70S6KCT104 at Thr412. (a)
NEK6 phosphorylates p70S6K. GST, GST-p70S6KCT104 (WT),
or the ATP site mutant GST-p70S6KCT104 (K123M) were
incubated with Mg2 [
-32P]ATP (0.1 mM) for 15 min at 30C in the
absence (-) or presence () of GST-NEK6 (WT). An autoradiograph
is shown in the upper two panels. (b) NEK6 phosphorylates
p70S6KThr412. Incubation as in (a), except for the additional presence
of GST-p70S6KCT104 (Thr412Ala). An anti-Thr412PO4
immunoblot is shown. (c) Time course of the NEK6-catalyzed
phosphorylation of p70S6KCT104 and p70S6KCT104
(Thr412Ala). GST-p70S6KCT104 (squares) or GST-
p70S6KCT104 (Thr412Ala) (circles) were incubated as in (a) with
either GST-NEK6 (open symbols) or the ATP site mutant GST-NEK6
(K74M, K75M) (closed symbols); the reactions were terminated at
the times indicated (minutes). 32P incorporation (mol PO4/mol
polypeptide) into the p70S6K variants is shown quantitatively and
by autoradiography. The bottom panel shows the time course of Thr412
phosphorylation by an Thr412PO4 immunoblot.
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Figure 4
NEK6 activates p70S6KCT104 in vitro and in vivo and synergizes shown in the lower panel. (b) Activation of p70S6KCT104 by NEK6
with PDK1. (a) Phosphorylation of p70S6KCT104 by NEK6 in in the absence or presence of PDK1. After the completion of steps 1
the absence and presence of PDK1. In the first stage of a three-stage and 2 described in (a), the activity of GST-p70S6KCT104 was
incubation, dephosphorylated GST-p70S6KCT104 is incubated in the assayed as the incorporation of 32P into the peptide substrate
presence of Mg ATP for 30 min, alone (open bars, lanes 1 and 2, 7 KKRNRTLTV (see Materials and methods). The error bars indicate 
and 8) or in the presence of GST-NEK6 (open bars, lanes 3 and one standard deviation of triplicate measurements from a single
4) or baculoviral PDK1 (open bars, lanes 5 and 6). In the second experiment; this experiment is representative of four replicates. (c)
stage, the vehicle (hatched bars, lanes 1 and 3) or PDK1 (hatched Activation of p70S6KCT104 by NEK6 in intact cells. The reporter
bars, lanes 2 and 4) was added to GST-p70S6KCT104 that had plasmid pEBG p70S6KCT104 (2 g) was coexpressed in CHO-IR
been previously incubated alone (lanes 1 and 2) or with NEK6 (lanes cells with pCMV5 FLAG vector alone (lanes 1 and 2), pCMV5 Myc-
3 and 4). In parallel, the vehicle (hatched bar, lanes 5 and 7) or NEK6 PDK1 alone (0.3 g, lane 7), or pCMV5 FLAG-NEK6 (0.1 g, lanes
(hatched bars, lanes 6 and 8) was added to GST-p70S6KCT104 that 3 and 5 or 0.3 g, lanes 4 and 6), alone (lanes 3 and 4) or with
in Stage 1 had received the vehicle (lanes 7 and 8) or PDK1 (lanes (lanes 5 and 6) pCMV5 Myc-PDK1 (0.3 g). After serum starvation
5 and 6). The reaction was continued for a further 30 min and was for 16 hr, cells were lysed and the activity of GST-p70S6KCT104
terminated by the addition of SDS electrophoresis buffer. The in GSH-Sepharose isolates was measured; the cell extracts were
incorporation of 32P during the first stage (open bars) and a second immunoblotted for Myc and FLAG, and the GSH isolates were
stage (hatched bars) is shown in the upper graph, a Coomassie blue immunoblotted for GST and Thr412PO4, as indicated. Similar results
stain of the incubation mixtures after SDS-PAGE is shown in the were obtained in three experiments.
middle panel, and an Thr412PO4 immunoblot of the transfer is
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ylation of p70S6K CT104 by NEK6 alone substantially p70S6KCT104 (Thr252Ala) (Figure 5a). Similarly, coex-
pression of increasing amounts ofMyc-PDK1withFLAG-activated p70S6K; moreover, NEK6 phosphorylation pro-
NEK6 in HEK293 cells does not alter the ability ofmoted PDK1-catalyzed p70S6 phosphorylation, and con-
FLAG-NEK6 to catalyze MBP phosphorylation in vitrocomitant phosphorylation of p70 by NEK6 and PDK1
(Figure 5c). Thus, PDK1 does not regulateNEK6 activity,provides a synergistic activation of the p70S6K. NEK6
either directly in vitro or by coexpression in vivo. Recipro-can also phosphorylate GST-PKB in vitro in a Ptd Ins
cally, the incubation in vitro of active GST NEK6 with3,4,5P3-independent manner, at a rate approximately 20%
baculoviral recombinant PDK1 results in negligible PDK1that of GST-p70S6KCT104 (Supplementary material).
phosphorylation, although GST-p70S6KCT104 is phos-
phorylated vigorously by GSTNEK6 in a parallel incuba-
The ability of NEK6 to activate p70S6KCT104 dur- tion (Figure 5b); moreover, PDK1 activity toward GST
PKB [in the presence of Ptd Ins (3,4,5)P3] is unaltereding transient expression was examined next. A GST-
by NEK6. Similarly, the coexpression of increasingp70S6KCT104 fusion protein, expressed in CHO cells
amounts of FLAG-NEK6 with Myc-PDK1 in HEK293that stably overexpress a recombinant human insulin re-
cells does not alter PDK1 activity toward GST PKB mea-ceptor (IR), is activated about 3-fold by insulin. This
sured in vitro. Thus, there is no crossregulation evidentincrease in S6K activity is concomitant with increased
between PDK1 and NEK6, and this finding indicates thatphosphorylation at p70S6KThr412 (Figure 4c; lanes 1 and
their synergistic activation of p70S6K is mediated at the2). Coexpression of p70S6KCT104 with NEK6 results
level of p70S6K itself.in a dose-dependent increase in p70S6K activity. This
increase is approximately 2-fold at 0.3 g NEK6 DNA
A kinase-deficient NEK6 interferes withand is concomitant with an increase in p70Thr412 phos-
insulin-stimulated p70S6KCT104phorylation (Figure 4c; lanes 3 and 4). Higher amounts activation and Thr412 phosphorylation
of NEK6 DNA result in substantial inhibition of the ex- The ability of NEK6 to activate p70S6K, in vitro and in
pression of the recombinant p70S6K polypeptide; such vivo, in a cooperative fashion with PDK1 is consistent
inhibition precludes analysis. Coexpression with PDK1 with a role for NEK6 in the physiologic regulation of
also activates GST-p70S6KCT104, with 0.3 g PDK1 p70S6K. To test further this possibility, we examined
DNA providing a 3-fold activation similar to that elicited whether a kinase-deficient NEK6 could interfere with the
by insulin (Figure 4c; lane 7). Although PDK1 is a rather ability of insulin to activate the p70S6K. NEK6 (K74M,
weak Thr412 kinase in vitro (Figure 4a; lanes 2 and K75M) was expressed in CHO-IR cells with GST-
5 versus lanes 8 and 3), the coexpression of p70S6K p70S6KCT104. Increasing amounts of inactive NEK6
with PDK1 in vivo results in robust phosphorylation at progressively repressed expression of the p70S6K; how-
Thr412PO4 (Figure 4c; lane 7 versus lane 2). The con- ever, at levels of kinase-inactive NEK6 that did not affect
comitant expression of NEK6 and PDK1 increases the expression of p70S6K reporter polypeptide, we ob-
p70S6K activity in a strongly cooperative fashion, more served an approximately 50% decrease in both the basal
than 10-fold greater than the sum of the effects of NEK6 and insulin-stimulated activity of p70S6KCT104. This
and PDK1 expressed individually with p70S6CT104 decrease was concomitant with a decrease in phosphoryla-
(Figure 4c; compare lanes 5 and 6 with lanes 4 and 7). tion at Thr412 (Figure 6). Thus, a kinase-inactive NEK6
This vigorous activation is accompanied by a clear-cut can interfere with the ability of insulin to phosphorylate
synergism in the phosphorylation at Thr412. Thus, NEK6 and activate the p70S6K.
alone activates p70S6K in vivo as well as in vitro and
acts synergistically with PDK1 both in the activation of NEK6 activity requires serine/threonine phosphorylation
and is sensitive to inhibitors of PI 3-kinasep70S6K and in the phosphorylation at p70S6KThr412.
Aliquots of recombinant FLAG-NEK6 that was immuno-
precipitated from transiently transfected HEK293 cells
PDK1 and NEK6 do not alter each other’s activity were treated with the serine/threonine protein phospha-
in vitro or in vivo tase PP2A in the presence or absence of Calyculin A. The
The clear-cut synergistic effect of NEK6 and PDK1 on reaction was terminated by the addition of Calyculin A
p70S6K activity, especially as observed during coexpres- to the previously untreated samples, and NEK6-catalyzed
sion in vivo, led us to inquire as to whether NEK6 acti- GST-p70S6KCT104 phosphorylation was measured
vates PDK1 or vice versa; this does not appear to be the (Figure 7a). PP2A abolished the ability of NEK6 to phos-
case. Under conditions in vitro where PDK1 catalyzes phorylate GST-p70S6KCT104 and caused the FLAG-
significant (Ptd Ins (3,4,5)P3-dependent) phosphorylation NEK6 polypeptide, which characteristically appears on
of a recombinant GST-PKB fusion protein, PDK1 cata- immunoblots as a doublet, to collapse to a single species,
lyzes negligible 32P incorporation into NEK6 [in the ab- corresponding to the faster migrating band (Figure 7a).
sence of Ptd Ins (3,4,5)P3] and does not alter NEK6 ac- The total amount of FLAG-NEK6 polypeptide is unal-
tered by PP2A, and the activity and electrophoretic mobil-tivity, measured as the phosphorylation of GST-
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Figure 5
PDK1 and NEK6 do not regulate each other. (a) PDK1 does not (lanes 2 and 3) or p70S6KCT104 (lanes 4 and 5) is shown in the
phosphorylate NEK6 directly in vitro. PP2A-treated GST-NEK6 autoradiograph. The Coomassie blue stain of GST-p70S6K and
(lanes 2 and 3) or GST-PKB plus Ptd Ins 3,4,5P3 (lanes 4 and 5) immunoblots of PDK1 and FLAG-NEK6 are shown below. The bar
were incubated alone (lanes 2 and 4) or with baculovirus graph on the right displays the ability of PDK1, incubated previously
recombinant PDK1 (lanes 3 and 5) for 15 min at 30C with Mg in the absence or presence of FLAG-NEK6 as described, to catalyze
[
-32P]ATP (100 M). The reaction mixtures were separated by the phosphorylation of GST PKB in the presence of Ptd Ins 3,4,5P3.
SDS-PAGE and transferred to PVDF membrane (left panel); the (c) Coexpression of FLAG-NEK6 with PDK1 does not alter the activity
autoradiograph (upper panel) Coomassie blue stain of GST PKB of NEK6 assayed in vitro. A fixed amount of pCMV5 FLAG-NEK6
and immunoblots of PDK1 and GST-NEK6 are shown. In the bar graph (0.3 g) was transiently expressed in CHO-IR cells alone or with
on the right, the kinase activity of GST NEK6, incubated previously increasing amounts of pCMV5 Myc-PDK1 (0.1, 0.3 g). The kinase
as indicated in the presence or absence of PDK1, toward GST- activity of NEK6 toward MBP is shown in the bar graph. (d)
p70S6KCT104 (Thr252Ala) is shown. (b) NEK6 does not Coexpression of Myc-PDK1 with NEK6 does not alter PDK1 activity
phosphorylate or activate PDK1 in vitro. PP2A-treated baculoviral assayed in vitro. A fixed amount of Myc-PDK1 (0.1 g DNA) was
PDK1 (lanes 2 and 3) or GST-p70S6KCT104 (lanes 4 and 5) transiently expressed alone or with increasing amounts of FLAG-
were incubated as in (a) in the absence (lanes 2 and 4) or presence NEK6. The kinase activity of Myc-PDK1 toward GST PKB, in the
(lanes 3 and 5) of FLAG-NEK6. 32P incorporation into PDK1 presence of Ptd Ins 3,4,5P3, was assayed in vitro.
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Figure 6 ment of cells with okadaic acid prior to extraction (Figure
7b). Concomitantly, okadaic acid caused an increase in
the fraction of NEK6 polypeptide migrating at the slower
electrophoretic mobility. We interpret these results as an
indication that NEK6 is activated by Ser/Thr phosphory-
lation; moreover, during transient expression the recombi-
nant NEK6 undergoes partial activation that can be mod-
estly augmented by phosphatase inhibitors and that
requires NEK6 catalytic activity. These findings presum-
ably reflect a need for autophosphorylation in vivo.
The phosphorylation of p70S6KThr412 in vivo in re-
sponse to insulin occurs in a PI 3-kinase-dependent man-
ner [10, 11]. We therefore investigated whether NEK6
activity ismodified by insulin or the PI 3-kinase inhibitors,
Wortmannin and LY294002. CHO-IR cells transiently ex-
pressing NEK6 were deprived of serum overnight; the
carrier, Wortmannin (100 nM), or LY294002 (50 M) was
added 30 min prior to the addition of buffer or insulin
(100 nM), and the cells were harvested 15 min later.
Insulin caused a modest increase (1.3- to 1.6-fold) in the
activity of recombinantNEK6,which increase was compa-
rable to that seen with okadaic acid (Figure 7c, lanes 5,8).
Insulin treatment also caused an increase in the proportion
A kinase-deficient NEK6 inhibits the basal and insulin-stimulated of NEK6 polypeptide in the more slowly migrating band
activity of p70S6KCT104. CHO-IR cells were transfected with on the immunoblot, and this increase was consistent
pEBG-encoded p70S6KCT104 alone (lanes 1 and 2) or together
with increased NEK6 phosphorylation. Wortmannin andwith pCMV5 FLAG-NEK6 (K74M, K75M; KD; lanes 3–8) in the
LY24002 each caused a 30%–50% decrease in the ba-amounts indicated. Following serum-deprivation for 16 hr, cells were
treated with the vehicle (lanes 1,6-8) or insulin (100 nM; lanes 2–5) sal and insulin-stimulated activity of NEK6. Insulin in-
for 10 min prior to extraction. The activity of GST-p70S6KCT104, creased the activity of endogenous p70S6K approximately
affinity purified on GSH-Sepharose from aliquots of cell lysates
1.5-fold in these experiments, and the basal and insulin-matched for protein, was assayed by the use of a synthetic peptide
stimulated p70S6K activity was inhibited by Wortmanninsubstrate (see Materials and methods). Aliquots of GSH isolates or
total cell lysate were resolved by 7.5% SDS-PAGE and immunoblotted and LY294002 (not shown). Recombinant NEK6 expres-
with GST-specific (top panel), phospho-Thr412-specific (middle sion gave a clear-cut increase in the Thr412 phosphoryla-panel), or FLAG-specific (bottom panel) antibodies. Similar results
tion of endogenous p70S6K2 (immunopurified from ali-were observed in three experiments.
quots of the same extracts; Figure 7, lane 2 versus 1) and
Thr412 phosphorylation was strongly suppressed by both
Wortmannin and LY294002. In contrast to the modest
ity of FLAG-NEK6 is not altered if PP2A treatment oc- inhibitory effects of Wortmannin and LY294002 pretreat-
curs in the presence of Calyculin A. Thus, NEK6 activity ment on recombinant NEK6, Rapamycin did not alter
requires NEK6 serine/threonine phosphorylation. It the mobility of recombinant NEK6 on SDS-PAGE or the
should be noted that the autophosphorylation of recombi- NEK6 kinase activity assayed after extraction.
nant NEK6 in vitro is confined to the upper band of
the doublet, and this observation suggests that only this Discussion
upper, phosphorylated NEK6 polypeptide possesses ki- This report demonstrates that, in rat liver, the major pro-
nase activity. Moreover, the slowed mobility of wild-type tein kinase activity capable of phosphorylating in vitro
NEK6 on SDS-PAGE after expression in vivo appears to Thr412 on the p70S6K comprises a mixture of two closely
require NEK6 catalytic activity in light of the fact that related 35 kDa protein kinases in the NIMA family; these
NEK6 (K74M, K75M) migrates as a single band whose protein kinases are designated NEK6 and NEK7. Consis-
mobility corresponds to the faster, inactive band observed tent with this conclusion, recombinant NEK6, isolated
with wild-type NEK6. after transient expression in mammalian cells, phosphory-
lates the p70S6K in vitro onThr412. This phosphorylation
is accompanied by activation of the p70S6K catalytic func-The effect of okadaic acid on the activity of recombinant
tion. In addition, NEK6 collaborates with PDK1 to pro-NEK6 expressed in HEK293 cells was examined. The
duce a synergistic increase in the catalytic activity ofactivity of FLAG-NEK6, expressed at several levels, was
enhanced modestly (between 10%-60%) by the pretreat- p70S6K, in vitro and especially in vivo. The mechanisms
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Figure 7
NEK6 activity requires serine/threonine phosphorylation. (a) The effect FLAG-NEK6 were serum deprived for 16 hr prior to treatment with
of PP2A on NEK6 activity in vitro. Aliquots of recombinant FLAG- the cell-permeable PP2A inhibitor okadaic acid (1 M) for 30 min.
NEK6 from transiently transfected HEK293 cells (lanes 2, 4, and 6) The phosphotransferase activity of immunoprecipitated FLAG-NEK6
or control FLAG IP (lanes 1, 3, and 5) were treated in vitro with is shown in the bar graph and autoradiograph. An anti-FLAG
(lane 3–6) or without (lanes 1 and 2) protein phosphatase 2A (PP2A, immunoblot is shown in the bottom panel. (c) NEK6 activity is enhanced
1 U/ml) in the presence (lanes 3 and 4) or absence (lanes 5 and by insulin and is sensitive to inhibitors of PI 3-kinase. CHO-IR cells
6) of Calyculin A (1 M) for 1 hr. at 30C. Calyculin A was then added transiently expressing the FLAG-NEK-6 expression vector were serum
to the samples that had not already received the drug (lanes 1, 2, deprived for 16 hr prior to treatment with the vehicle (lane 2),
5, and 6), and NEK6 activity was assessed by the measurement of Wortmannin (100 nM, lanes 3 and 6), or LY294002 (50 M, lanes
its ability to catalyze 32P incorporation from [
-32]ATP into GST- 4 and 7). Thirty minutes later, the vehicle (lanes 1–4) or insulin (100
p70S6KCT104 (top and middle panels). The effect of PP2A nM, lanes 5–8) was added, and the cells were extracted 15 min later.
treatment on the electrophoretic mobility of NEK6 polypeptide is The activity of FLAG-NEK6 toward MBP is shown in the bar graph,
shown in the anti-FLAG immunoblot (lowest panel). (b) The effect of and immunoblots of recombinant FLAG-NEK6 and endogenous
okadaic acid on NEK6 activity in intact cells. HEK293 cells transiently p70S6K2 polypeptide and Thr412PO4 are shown below. This is
transfected with increasing quantities (0–3 g) of pCMV5 representative of four replicates.
by which NEK6 and PDK1 cooperate to generate a syner- coexpression in vivo is much more robust than that ob-
served for purified PDK1 and NEK6 in vitro suggestsgistic activation of p70S6K are not entirely known, but
they do not appear to involve any crossactivation of NEK6 that additional factors necessary for the full activation of
p70S6K remain to be identified.by PDK1 or vice versa. Based on in vitro experiments, it
appears that prior phosphorylation of p70S6K by NEK6
Themammalian family ofNIMA-related kinases orNEKsincreases both the extent of phosphorylation achieved by
currently numbers seven. NIMA, the founding member,a subsequent incubation with PDK1 as well as the size
is an Aspergillus nidulans gene product required, in collabo-of the increase in p70S6K catalytic activity engendered
ration with cdk1, for the initiation and progression ofby any level of PDK1-catalyzed p70S6K phosphorylation.
mitosis [23]. The functions of the mammalian NIMA-These responses are consistent with the previous demon-
related kinases are in general poorly understood. Thestrations that the substitution of an acidic residue for
similarity between NIMA and the mammalian NIMA ho-Thr412 enhances the binding of PDK1 to p70S6K and
mologs is largely confined to their (usually) amino-termi-that the simultaneousmodification of Thr252, the primary
site of PDK1 phosphorylation, and Thr412 generates a nally located catalytic domains, which share 40%–50%
amino acid sequence identity. NEKs 1–3 contain com-strong, positively cooperative activation of p70 catalytic
activity [15]. Nevertheless, NEK6 clearly phosphorylates pletely distinct, nonhomologous carboxy-terminal noncat-
alytic tails, implying distinct functions and/or regulation.sites on p70S6K other than Thr412; the identification of
those sites and their contribution to the regulation of For example, NEK2 is centrosome-associated and, like
NIMA, shows peak expression at the G2M boundary [24].p70S6K is yet to be determined. Moreover, the fact that
the activation of p70S6K elicited by NEK6 and PDK1 NEK2 is implicated in centrosome separation through the
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phosphorylation of the centrosome-associated polypep- Thr412 phosphorylation in vitro, it greatly diminishes
insulin-stimulated p70S6KThr412 phosphorylation intide NAP2 [25]. In contrast, NEK3 is a cytoplasmic en-
zyme that is somewhat more abundant in G0 and shows vivo [10].
little variation in activity across the cell cycle [26].
As regards NEK6, its ability to phosphorylate and activate
p70S6K both in vitro and in vivo and to act synergisticallyNEK6 is the third protein kinase reported to phosphory-
late p70S6KThr412, the others being mTOR [18, 19] and with PDK1 is supportive of a physiologic role. In addition,
overexpression of a mutant, inactive NEK6 interferes sig-PDK1 [21] itself. Themost significant question is whether
any of these function physiologically as p70S6KThr412 nificantly with the ability of insulin to activate p70S6K
and promote Thr412 phosphorylation; this finding sug-kinases, and under what circumstances. The mTOR ki-
nase phosphorylates p70S6K at Thr412 and several other gests that NEK6 can interact with and sequester one or
more of the elements necessary for the insulin activationsites in vitro, and it collaborates in vitro with PDK1 in a
manner quite similar to that described herein for NEK6; of p70S6K. In light of the fact that insulin-stimulated
p70Thr412 phosphorylation is inhibited by Wortmanninphosphorylation of p70S6K by mTOR increases p70S6K
catalytic activity per se and substantially amplifies the and LY294002, we anticipated that the responsible pro-
tein kinase would also be activated by insulin and inhib-activation of p70S6K induced by a subsequent phos-
phorylation by PDK1 [19]. The phosphorylation of ited by Wortmannin and LY294002. It is evident that
recombinant NEK6 spontaneously acquires significant ca-p70S6KThr412 is strongly inhibited in vivo by the highly
specific mTOR inhibitor, Rapamycin [20]. Moreover, the talytic activity during transient expression in mammalian
cells; this activity can be abolished by treatment withactivity of mTOR (at least as assayed in vitro with eIF-
4E BP as a substrate) is reported to be modestly increased PP2A in vitro. Coexpression with PDK1 does not increase
NEK6 activity further, although PDK1 strongly activatesby insulin [27]. Nevertheless, several observations suggest
that although an active mTOR is critical for the insulin- p70S6K. Thus, NEK6 is not a PDK1-activated kinase.
The activity of recombinant NEK6 is increased modestlystimulated phosphorylation of p70Thr412 in vivo, this
requirement is not attributable to mTOR’s ability to act (30%–60%) by treatment in vivo with okadaic acid; this
increase is associated with slowed mobility on SDS-directly as an insulin–stimulated p70S6KThr412 kinase.
PAGE, and a comparable mild activation is elicited inThus, the properties and specificity of the eIF-4E BP-
response to insulin. The physiologic significance of thisand p70S6K-directed kinase activities of mTOR are quite
modest insulin stimulation is uncertain. The small activa-distinct, and we have been unable to detect any insulin-
tion may reflect an artefactually high basal activity associ-induced increase in themTORkinase activity assayed with
ated with transient overexpression. The relatively higha p70S6K substrate [19]. In addition, the p70S6K mutant
basal activity of recombinant NEK6 is modestly inhibited2-46/CT104, which is resistant to inhibition by Rapa-
by the PI 3-kinase inhibitors, Wortmannin and LY294002,mycin in vivo, nevertheless undergoes substantial insulin-
at concentrations that engender strong inhibition ofstimulated phosphorylation of Thr412 and activation in
p70S6K. This finding indicates that the dependence ofvivo in the presence of Rapamycin concentrations far in
recombinant NEK6 activity on PI 3-kinase activity is onlyexcess of those required for complete dephosphorylation
partial. Thus, the regulatory inputs that control NEK6of Thr412 on wild-type p70S6K and maximal inhibition of
activity under physiologic conditions, apart from its de-mTOR [20]. In view of these observations, we and others
pendence on phosphorylation, are as yet unclear. Ourhave suggested that mTOR regulates p70S6KThr412
efforts to evaluate the regulation of endogenous NEK6/7phosphorylation in vivo primarily by the inhibition of a
have been hampered by an inability to generate antibodiesThr412 phosphatase, probably PP2A [20, 28].
capable of immunoprecipitating endogenous NEK6/7
polypeptides; cell lines expressing recombinant NEK6As regards PDK1, although its ability to phosphorylate
are currently in preparation.p70Thr412 in vitro is less than 5% that of p70S6KThr252,
coexpression of PDK1 with p70S6K engenders consider-
In conclusion, NEK6 is a NIMA-related protein kinaseable p70S6KThr412 phosphorylation [15, 21]. In addition,
that is a novel candidate regulator of the p70S6K. It isPDK1 activity is necessary for p70S6KThr412 phosphory-
capable of phosphorylating and activating this ribosomallation in vivo; ES cells lacking PDK1 exhibit no IGF-1
protein kinase in vitro and in vivo.stimulated phosphorylation of p70S6KThr412 [17]. Thus,
PDK1 may participate directly as a Thr412 kinase in vivo
Materials and methodsor may be necessary for the activation in vivo of a
Assay of Thr412 kinase activityp70S6KThr412 kinase. Alternatively, the requirement for
Each kinase reaction (30 l) contained 5 l of extract (or buffer B asPDK1 in Thr412 phosphorylation may arise at a substrate
a control), 1 g of Rapamycin-treated baculoviral p70S6KCT104, 50level; we have observed that although the conversion of mM MOPS, 10 mM MgCl2, 2 mM EGTA, 1 mM DTT, 20 mM -glycero-
p70S6KThr252, the primary site of PDK1-directed phos- phosphate, and 1 M Calyculin A. The reactions were initiated by the
addition of nonradioactive ATP to a final concentration of 100 M.phorylation, to Ala has no effect on PDK1-catalyzed
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Assays were carried out at 30oC for 10 minutes and terminated by the tube) precoupled to Protein G-Sepharose was added to aliquots of
supernatant containing equal amounts of total protein and incubated foraddition of 10 l 4 Laemmli sample buffer. Samples were resolved by
SDS-PAGE, transferred to PVDF membrane, and immunoblotted with 3 hr at 4oC. Immunoprecipitates were washed three times in lysis buffer,
three times in lysis buffer containing 0.5 M LiCl, and three times in kinaseanti-phospho-Thr412 specific antibodies as described in [10]. As a
positive control for the phospho-Thr412 Western blot, active, recombi- buffer (50 mM MOPS, 10 mM MgCl2, 2 mM EGTA, 1 mM DTT, 20 mM
-glycerophosphate, and 1M Calyculin A). An assay of immunoprecipi-nant p70S6KCT104, purified from Sf9 cells coinfected with baculoviral
p70S6KCT104 and a constitutively active PI 3-kinase p110 catalytic tated recombinant NEK6 was carried out under conditions identical to
those described for the assay of rat liver kinase activity towardsubunit [12], was run in a separate lane.
p70S6KThr412 (see above) except that nonradioactive ATP was re-
placed by 10 M [
-32P]ATP (5000–6000 cpm/pmol), and occasionallyCloning of NEK6 and NEK7 and construction
myelin basic protein (0.5 mg/ml) was used in place of p70S6KCT104.of expression vectors
Phosphate transfer into NEK6 substrate was quantified by liquid scintilla-The entire open reading frame of human NEK6 and mouse NEK7 was
tion counting.derived by interrogation of the dbEST database at the National Center
for Biological Information (http://www.ncbi.nlm.nih.gov/dbEST/index.html)
For evaluation of the regulation by NEK6 and/or PDK1 offor overlapping est sequences. In addition, a ZAP II F442A mouse
p70S6KCT104 in intact cells and the ability of kinase-deficient NEK63T3 L1 adipocyte cDNA library was screened by the polymerase chain
to interfere with insulin activation of p70S6KCT104 in intact cells, CHO-IRreaction (PCR) and the use of nested forward or reverse primers corre-
cells were cotransfected with the appropriate pCMV5 expression con-sponding to complementary sequences within regions found to be invari-
structs (or empty vectors) together with pEBG2T p70S6KCT104 asable in overlapping ESTs (encoding subdomain II of mouse NEK7 kinase
the reporter plasmid; a constant total amount of DNA was used. GST-domain and subdomain VIb of mouse NEK6) and primers annealing to
p70S6KCT104 was affinity purified from cell lysates on GSH-Sepha-the T3 and T7 promoters in ZAP II. Confirmation of the sequence of
rose, and its activity was measured by a peptide kinase assay, describedthe entire open reading frame of mouse NEK6 and NEK7 was achieved
below.by automated DNA sequence analysis of PCR fragments. Amplification
by PCR of the open reading frame of human NEK6 was obtained from
Activation of p70S6KCT104 by NEK6 and/or PDK1 in vitroa human skeletal-muscle cell library by the use of the forward primer
GST-p70S6KCT104 purified from Rapamycin-treated HEK293 cells5-CCGGAATTCTATGGCAGGACAGCCCGGCCACATGCCCCAT
was further dephosphorylated with PP2A in a buffer containing 50 mMGGAGGGAGTTCC-3 and the reverse primer 5-GGCGAATTCTCAG
Tris (pH 8.0), 0.1 mM EGTA, 1 mM DTT and 1U/ml PP2A. After incuba-GTGCTGGACATCCAGATGTGCAT-3. The product was subcloned
tion at 30oC for 30 min, Calyculin A was added to a final concentrationas an EcoRI fragment into the mammalian expression vector pCMV5-
of 10 M. The activation of GST-p70S6KCT104 by NEK6 and/orFLAG, screened for correct orientation by digestion with BamHI, and
PDK1 in vitro was carried out in three stages. In the first stage, a 5 lverified by DNA sequencing. An identical approach was used for the
aliquot of either GST-NEK6 (1.2 g), baculoviral PDK1 (2.2 g), or thegeneration of a pCMV5-FLAG-NEK7 expression construct, for which
vehicle was added to 2g PP2A-treated GST-p70S6KCT104 or GST.the forward primer 5-CCGGAATTCTATGGATGAACAATCACAAG
The phosphorylation reaction (25 l), containing 50 mM MOPS (pHGAATGCAAG-3 and the reverse primer 5-CCGGAATTCCTATTAGG
7.4), 10 mM MgCl2, 2 mM EGTA, 20 mM -glycerophosphate, and 1TGCTTGCGGTACATGCATGC-3 were used, with both mouse embry-
M Calyculin A, was initiated by the addition of unlabeled ATP (100onic or T-cell cDNA libraries as a template.
M) and incubated for 30 min at 30oC. After stage 1, reactions were
placed on ice. In the second stage of the assay, 15 l of either GST-A kinase-deficient version of NEK6 was constructed by PCR mutation of
NEK6 (1.2 g), baculoviral PDK1 (2.2 g), or the vehicle diluted in theboth K74 and K75, lysine residues presumably critical for ATP phosphate
same kinase buffer constituents (including 100 M unlabeled ATP) wasbinding, to M. Subcloning both wild-type and K74M/K75M NEK6 variants
added to the appropriate tubes, which were incubated for a furtherinto the pEBG2T plasmid enabled the expression of NEK6 variants as
30 min at 30C. In stage 3, the activity of GST-p70S6KCT104 wasGST-fusion proteins in mammalian cells. The construction of pEBG
measured by the use of a synthetic peptide as a substrate; two equalp70S6K1CT104 variants and Myc-tagged PDK1 has been described
aliquots were taken from each tube and mixed with the vehicle or thepreviously [15].
p70S6K substrate peptide KKRNRTLTV. The p70S6K reaction (40 l
containing 100M KKRNRTLTV peptide and 100 M [
-32P]ATP (200–Northern analysis
400 cpm/pmol) was initiated by the addition of [
-32P]ATP and terminatedA blot of murine mRNA purchased from Clontech was sequentially hybrid-
after 10 min at 30oC by spotting onto P81 phosphocellulose paper. Theized with a 32P-labeled PCR fragment of NEK6 (281 nucleotides), NEK7
filters were washed in 75 mM H3PO4 and quantified by liquid scintillation(270 nucleotides), and beta-actin under standard conditions.
counting. The amount of peptide-incorporated 32P that was attributed
specifically to p70S6K activity was calculated by subtraction of the 32P-Cell culture and transient transfections
cpm from identical control reactions containing GST rather than GST-HEK293 cells were maintained in Dulbecco’s modified Eagle’s medium
p70S6KCT104. There was no difference in the filter-bound 32P-cpm(DMEM) supplemented with 10% fetal calf serum (FCS; Sigma) at 37oC
in reactions with GST- p70S6KCT104 or GST when the peptide wasin an atmosphere containing 5% CO2. CHO-IR cells were maintained absent. One unit (U) of p70S6K activity is defined as the incorporationunder 0.66 g/ml Geneticin (Gibco BRL) selection in Ham F-12 nutrient
of 1 nmol phosphate into KKRNRTLTV peptide per minute.mixture (Gibco BRL) supplemented with 10% FCS.
Phosphorylation of GST-p70S6KCT104 by NEK6For the examination of NEK6 regulation in CHO-IR cells, 10 cm plates
and/or PDK1at 80% confluency were transfected with pCMV5 FLAG-NEK6 plasmid
For quantification of the amount of phosphate incorporated into GST-DNA (0.03–1g) in 5 ml OPTI-MEM1 media by the use of Lipofectamine
p70S6KCT104 by NEK6 and/or PDK1 in each stage of the assayreagent (Gibco BRL) according to the manufacturers instructions. After
described above, identical reactions were carried out in parallel except5 hr, cells were supplemented with 5 ml Ham F-12 (20% FCS) media
that [
-32P]ATP (2000–3000 cpm/pmol) was used instead of unlabeledcontaining 0.66 g/ml Geneticin. After 16 hr, the medium was replaced
ATP during the first and second stages. These reactions were terminatedwith Ham F-12 (10% FCS) media. After a further 10 hr, the cells were
by the addition of Laemmli sample buffer (1 final concentration). Sam-serum-deprived overnight (16 hr) before treatment with Wortmannin,
ples were resolved by SDS-PAGE and transferred to PVDF membrane.LY294002, and/or insulin. Cells were extracted in ice-cold buffer A
After Coomassie blue staining and visualization by autoradiography, thesupplemented with Complete protease inhibitor cocktail (1 tablet/50
membranes were immunoblotted with anti-phospho-Thr412 specificmls), 50 nM Calyculin A, 1 mM Na3VO4, and 0.2% Triton X-100 and
centrifuged for 20 minutes at 13,000  g. Anti-FLAG antibody (2 g/ antibodies. Coomassie-stained bands corresponding to GST-
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P, et al.: The role of 3- phosphoinositide-dependent proteinband was quantified.
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